Answers are grounded in this paper and cite their sources.
Bruton tyrosine kinase inhibitors have dramatically changed the management of patients with chronic lymphocytic leukemia over the past decade. Despite clear efficacy of this class in the treatment of chronic lymphocytic leukemia, cardiovascular complications of Bruton tyrosine kinase inhibitors remain one of the most common reasons for discontinuation of anticancer therapy. This review focuses on cardiovascular complications of Bruton tyrosine kinase inhibitors and recommendations for the management of patients with chronic lymphocytic leukemia undergoing anticancer therapy.
No takes yet. Share an insight, caveat, or question.
ERGASHEVA et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: